Why Did My Botox Stop Working? Neutralizing Antibodies and Treatment Failure

Botulinum toxin type A injections—commonly known by brand names like Botox, Dysport, Xeomin, and Daxxify—are the most frequently performed cosmetic procedures in the world. For millions of patients, these neuromodulators provide reliable, predictable smoothing of dynamic wrinkles, such as glabellar frown lines, forehead lines, and crow's feet, for three to four months at a time.

But for a small subset of long-term patients, a frustrating phenomenon occurs: a treatment that worked perfectly for years gradually or suddenly stops producing results. The wrinkles do not soften, the target muscles retain full movement, and the duration of the effect collapses from months to weeks, or even days.

When this happens, patients and injectors alike are faced with a clinical puzzle. Did the product fail? Was the technique flawed? Or has the patient's immune system developed "immunity" to the toxin?

Understanding the differences between primary non-response, non-immunogenic secondary failure, and true antibody-mediated secondary treatment failure is essential for determining the next clinical steps. This guide maps the biological mechanisms, diagnostic options, per-product formulation profiles, and evidence-based strategies for resolving treatment failure.

---

Did My Botox Actually Stop Working, or Is It the Injector, the Dose, or Storage?

Before assuming that your body has developed immunity to botulinum toxin, it is critical to distinguish between two broad categories of treatment failure: primary non-response (the treatment never worked) and secondary treatment failure (the treatment worked initially but stopped working over time).

Primary Non-Response: Technique, Dosing, and Product Integrity

If a patient receives botulinum toxin and experiences little to no muscle relaxation after two weeks, this is defined as primary non-response. True biological primary non-response—where a patient's muscles lack the necessary receptors or intracellular machinery to bind the toxin—is exceedingly rare. In nearly all cases, primary non-response is caused by external, non-immunogenic factors:

1. Underdosing (Insufficient Units): The clinical effect of botulinum toxin is strictly dose-dependent. If the injector administers too few units for the mass and strength of the target muscle, the muscle will not be adequately paralyzed. For example, the FDA-approved dose for glabellar lines is 20 units of Botox or Jeuveau, or 40 units of Daxxify. Injecting a "baby Botox" dose (e.g., 10 units of Botox across the glabellar complex) in a patient with strong, hyperfunctional muscles will result in incomplete relaxation and a very short duration of action.
2. Dilution and Reconstitution Errors: Botulinum toxins are shipped as dry, vacuum-dried, or lyophilized powders that must be reconstituted with sterile saline (sodium chloride 0.9%). If the injector uses too much diluent, the concentration of the toxin per injection volume drops. While the total number of units remains the same if the entire volume is injected, a highly diluted solution can diffuse too widely, spreading to non-target muscles and weakening the concentrated effect in the target muscle.
3. Cold-Chain Transport and Storage Failures: Botulinum neurotoxin is a highly delicate, thermally sensitive protein. OnabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) must be shipped and stored under strict refrigeration (2°C to 8°C) or freezing conditions depending on the formulation. If the vial is exposed to room temperature during shipping, or if it sits unrefrigerated in a clinic, the protein structure will denature. Once denatured, the toxin cannot bind to nerve terminals. Reconstituted vials are also highly sensitive; while clinical guidelines suggest they remain stable for up to four weeks when refrigerated, structural degradation begins as soon as the saline is introduced.
4. Anatomic Targeting and Muscle Recruitment: Injecting neuromodulators requires precise placement within the belly of the target muscle (e.g., the frontalis for forehead lines, or the corrugator supercilii and procerus for glabellar lines). If the injection is placed too superficially (in the dermis rather than the muscle) or off-target, the toxin will not reach the neuromuscular junctions. Furthermore, as patients age, they may naturally recruit adjacent, untreated muscles to perform the same facial expressions, giving the false impression that the treated muscle is still fully active.

Secondary Treatment Failure: The True Loss of Response

Secondary treatment failure is defined as the progressive or complete loss of clinical efficacy after a patient has experienced at least two or more successful, consecutive treatments. In this scenario, the injector, dose, reconstitution, and storage remain constant, but the duration of effect progressively shortens (e.g., wearing off after 2–4 weeks instead of 12–16 weeks) until the treatment fails to produce any visible muscle relaxation.

While secondary failure can occasionally be caused by changes in the patient's anatomy—such as age-related muscle hypertrophy or severe tissue laxity—it is the scenario where the patient's immune system is most likely to be involved.

---

What Are Neutralizing Antibodies, and How Often Do They Cause Botox to Fail?

Because botulinum neurotoxin is synthesized by the bacterium Clostridium botulinum, the human immune system recognizes it as a foreign antigen. When the toxin is injected into facial tissues, it is encountered by antigen-presenting cells (APCs), such as dendritic cells and macrophages. These cells ingest the protein, process it, and present its peptide fragments to T-helper cells, which in turn stimulate B-cells to produce antibodies specifically targeted against the toxin.

Binding vs. Neutralizing Antibodies

It is crucial to understand that not all antibodies generated against botulinum toxin will cause treatment failure. The immune response produces two types of antibodies:

• Binding Antibodies (BABs): These antibodies bind to various sites (epitopes) on the toxin molecule or its complexing proteins. However, they do not interfere with the active, functional domains of the neurotoxin. A patient can have high titers of binding antibodies and still experience full, normal muscle relaxation from their injections.
• Neutralizing Antibodies (NABs): These antibodies specifically bind to the functional domains of the 150 kDa active neurotoxin molecule. Most commonly, they target the heavy chain's receptor-binding domain, preventing the toxin from attaching to the presynaptic receptors (SV2 and gangliosides) on the nerve terminal. They can also target the light chain, blocking its enzymatic (zinc-endopeptidase) activity. When neutralizing antibodies are present in sufficient titers, they bind to the injected toxin and flag it for rapid clearance by the immune system before it can enter the nerve terminal. The result is clinical treatment failure.

[Injected Toxin] ──► Encountered by Dendritic Cells (APCs)
                         │
                         ▼
                   T-Cell Activation
                         │
                         ▼
                   B-Cell Stimulation
                         │
        ┌────────────────┴────────────────┐
        ▼                                 ▼
[Binding Antibodies (BABs)]     [Neutralizing Antibodies (NABs)]
  • Bind non-active sites         • Bind receptor-binding domain
  • No effect on clinical result  • Block cell entry & cleave function
  • Toxin still works             • Clinical Treatment Failure

What the Clinical Data Actually Shows

Many clinic websites minimize the risk of antibody formation, stating that "immunity" is an urban legend or "extremely rare." However, peer-reviewed, long-term clinical data paints a more nuanced picture. The rate of neutralizing antibody formation depends heavily on whether the toxin is used for cosmetic purposes (low doses, typically 20–60 units per session) or therapeutic purposes (high doses for cervical dystonia, spasticity, or chronic migraine, typically 100–400 units per session).

• Pooled Rate Across All Indications (~2.1%): A systematic review and meta-analysis by Lacroix-Desmazes pooled 31 studies covering 5,811 subjects treated with current (post-1997) type A formulations across various medical and cosmetic indications (Botox, Dysport, and Xeomin). Only about 2.1% of these patients had measurable neutralizing antibodies. Because this pooled figure includes high-dose therapeutic use, the true rate at cosmetic doses sits at the low end of this range — but it is not "near-zero," and even ~2% represents a real clinical population across the millions of aesthetic injections performed each year.
• Therapeutic Cohort Prevalence (13.9%): For patients receiving high-dose, long-term therapeutic treatments, the risk is significantly higher. A landmark cohort study by Albrecht et al., published in Neurology (2019), evaluated 596 patients undergoing continuous botulinum toxin therapy for neurological conditions. They found that 13.9% (83 of 596 patients) developed neutralizing antibodies. The study demonstrated that the risk of NAb development was directly correlated with higher cumulative doses, shorter treatment intervals, and longer treatment durations (prevalence exceeded 10% after 10+ years of continuous therapy).
• The Antibody Share of Secondary Failure (53.6%): Importantly, if your Botox stops working, it does not guarantee you have antibodies. A meta-analysis by Fabbri et al. (2016) evaluated patients experiencing true secondary non-response. They found that neutralizing antibodies were present in 53.6% of these secondary non-responders. This means that roughly 46.4% of patients who experience secondary failure are actually failing for non-immunogenic reasons (such as changes in muscle recruitment, sub-threshold dosing, or poor injection technique). Identifying whether antibodies are truly present is therefore the critical first step before altering the treatment plan.

---

Which Toxins Are Less Likely to Trigger Antibodies (and Why Accessory Proteins Matter)?

To understand why some botulinum toxin formulations are more immunogenic than others, we must look at the molecular structure of the products.

In its natural state, the Clostridium botulinum bacterium produces the active 150 kDa neurotoxin molecule wrapped inside a shell of protective, non-toxic accessory proteins. These include non-toxic non-hemagglutinin (NTNHA) proteins and various hemagglutinin (HA) proteins (such as HA-17, HA-33, HA-19, and HA-70). Together, the active neurotoxin and these accessory proteins form large molecular complexes, ranging from 300 kDa to 900 kDa.

       NATURAL BOTULINUM TOXIN COMPLEX (e.g., Botox - 900 kDa)
┌─────────────────────────────────────────────────────────────┐
│  [Accessory Proteins: HA-17, HA-33, HA-19, HA-70, NTNHA]     │
│  ┌───────────────────────────────────────────────────────┐  │
│  │  [Active Neurotoxin Core - 150 kDa]                   │  │
│  │  (Cleaves SNAP-25, blocks acetylcholine release)       │  │
│  └───────────────────────────────────────────────────────┘  │
└─────────────────────────────────────────────────────────────┘
      *Accessory proteins act as immunological adjuvants, 
       increasing the risk of antibody formation.

The Adjuvant Effect of Complexing Proteins

For decades, it was assumed that these complexing proteins were necessary to stabilize the active neurotoxin and protect it from enzymatic degradation in the tissue. However, basic immunology and clinical studies have demonstrated that these accessory proteins act as immunological adjuvants.

An adjuvant is a substance that enhances the body's immune response to an antigen. When a 900 kDa complex (like Botox) is injected, the large cluster of foreign proteins triggers a stronger inflammatory response, recruiting more antigen-presenting cells to the site. The APCs process both the accessory proteins and the active neurotoxin, presenting them to T-cells. This adjuvant effect increases the likelihood that the immune system will synthesize neutralizing antibodies against the active 150 kDa neurotoxin core.

If the accessory proteins are removed, leaving only the pure 150 kDa active neurotoxin molecule, the immunological trigger is substantially weakened. The immune system is far less likely to recognize the pure, uncomplexed protein, thereby reducing the rate of antibody synthesis.

Comparing the Formulations

Currently, the major FDA-approved botulinum toxin type A products on the market fall into two categories: complexing-protein-containing toxins and complexing-protein-free (CPF) toxins.

• OnabotulinumtoxinA (Botox / Botox Cosmetic): This formulation is a fully complexed 900 kDa macromolecule containing the 150 kDa active neurotoxin wrapped in NTNHA and hemagglutinin proteins. It has the longest track record but also carries the full accessory-protein complement.
• AbobotulinumtoxinA (Dysport): Dysport contains a mixture of complex sizes, primarily around 500 kDa to 900 kDa. Like Botox, it retains the accessory hemagglutinins and NTNHA proteins. Because of its formulation, it has a higher active protein load per labeled unit compared to other products, which must be considered in cumulative antigen calculations.
• PrabotulinumtoxinA-xvfs (Jeuveau): Jeuveau is formulated as a 900 kDa complex, structurally and biochemically highly similar to Botox. It carries the same accessory proteins and is processed by the immune system in an identical manner.
• IncobotulinumtoxinA (Xeomin): Xeomin is the pioneer of complexing-protein-free toxins. During manufacturing, the accessory proteins are entirely separated from the neurotoxin through a specialized chromatography process, leaving only the pure 150 kDa active neurotoxin. Clinical trials have demonstrated that Xeomin has a highly favorable immunogenicity profile, with virtually no documented cases of neutralizing antibody formation in treatment-naïve cosmetic patients.
• DaxibotulinumtoxinA-lanm (Daxxify): Daxxify is a modern complexing-protein-free toxin. It consists of the pure 150 kDa neurotoxin core formulated without any human or animal-derived proteins. Instead, it is stabilized by a proprietary, positively-charged synthetic peptide (RTP004). The positively charged peptide binds electrostatically to the negatively charged neurotoxin, preventing aggregation and enhancing binding to the cell membrane. Large-scale clinical trials (the SAKURA program) reported that Daxxify did not show an elevated immunogenicity signal, confirming that the synthetic peptide does not act as an adjuvant.

---

How Is Antibody-Mediated Failure Diagnosed — Frontalis Test, EDB Test, and the MHDA Assay?

If a patient presents with secondary treatment failure, switching brands immediately without a diagnosis is a poor clinical strategy. If the failure is caused by neutralizing antibodies, switching to another standard complexing-protein-containing toxin will be useless. If the failure is non-immunogenic (e.g., underdosing or poor technique), the patient does not need to switch to high-cost alternatives or take a multi-year break.

Clinicians use a diagnostic ladder to confirm or rule out antibody-mediated failure:

                  DIAGNOSTIC LADDER FOR BOTOX FAILURE
┌───────────────────────────────────────────────────────────────────┐
│ [Level 3: Mouse Hemidiaphragm Assay (MHDA)]                       │
│ • Gold-standard ex-vivo bioassay; measures muscle contraction.     │
│ • Highly sensitive (detection limit ~1.82 mIU/mL); expensive.     │
└─────────────────────────────────┬─────────────────────────────────┘
                                  ▲
                                  │ Confirm positive/borderline
┌─────────────────────────────────┴─────────────────────────────────┐
│ [Level 2: Extensor Digitorum Brevis (EDB) Test]                   │
│ • EMG-guided quantitative in-vivo test.                           │
│ • ~80% Sensitivity / ~94% Specificity.                            │
└─────────────────────────────────┬─────────────────────────────────┘
                                  ▲
                                  │ Screen asymmetric response
┌─────────────────────────────────┴─────────────────────────────────┐
│ [Level 1: Bedside Unilateral Frontalis Test]                     │
│ • Inject 2-4 units into one side of forehead.                    │
│ • Observe for asymmetric brow-raise loss at 2 weeks.              │
└───────────────────────────────────────────────────────────────────┘

Level 1: The Bedside Unilateral Frontalis Test

The simplest, most cost-effective diagnostic screen is the unilateral frontalis test. It is highly favored by dermatologists and injectors, with surveys showing that over 68% of clinicians use it as their primary in-office assessment for suspected toxin resistance.

• Procedure: The injector identifies a patient with active forehead movement. They inject a small, standard dose of botulinum toxin (typically 2 to 4 units of Botox/Xeomin/Jeuveau, or 4 to 8 units of Daxxify) into the middle of the frontalis muscle on only one side of the forehead. The other side is left entirely untreated.
• Evaluation: The patient returns to the clinic 14 days later. The injector instructs the patient to raise their eyebrows as high as possible.
  • Normal Response (No Antibodies): The injected side of the forehead remains completely smooth and immobile, while the untreated side wrinkles normally, resulting in a dramatic asymmetry of the brows. This proves that the patient's muscles are biologically responsive to the toxin, indicating that the previous failure was likely due to injector technique, underdosing, or product degradation.
  • Negative Response (Neutralizing Antibodies Present): Both sides of the forehead wrinkle symmetrically, and there is no difference in brow height or muscle movement. Because the active, fresh toxin failed to produce any relaxation under controlled conditions, the presence of neutralizing antibodies is highly suspected.

Level 2: The Extensor Digitorum Brevis (EDB) Test

For a quantitative, objective in-vivo measurement, clinicians can perform the Extensor Digitorum Brevis (EDB) test. The EDB is a small muscle located on the dorsum (top) of the foot that controls the extension of the toes.

• Procedure: An electromyography (EMG) technician records the baseline compound muscle action potential (CMAP) of the EDB muscle. The clinician then injects a high, concentrated dose of botulinum toxin (typically 10 to 20 units of Botox) directly into the EDB muscle.
• Evaluation: After 14 days, the patient returns for follow-up EMG testing.
  • If the patient has no antibodies, the EDB muscle will be paralyzed, resulting in a drop in the CMAP amplitude of at least 50% to 80% compared to baseline.
  • If the patient has high titers of neutralizing antibodies, the CMAP amplitude remains unchanged or shows minimal reduction. Clinical studies have shown that the EDB test has a sensitivity of approximately 80% and a specificity of 94% for detecting clinically relevant neutralizing antibodies, making it an excellent bridge between bedside testing and laboratory assays.

Level 3: The Mouse Hemidiaphragm Assay (MHDA)

The absolute gold standard for confirming neutralizing antibodies is the ex-vivo Mouse Hemidiaphragm Assay (MHDA). Because it requires live animal tissue and specialized laboratory equipment, it is primarily reserved for clinical research, regulatory trials, or complex therapeutic cases.

• Procedure: A blood sample is drawn from the patient to isolate their serum. In the laboratory, the patient's serum is incubated with a known, standardized concentration of botulinum neurotoxin. The mixture is then applied to an isolated nerve-muscle preparation—specifically, a mouse hemidiaphragm muscle with the phrenic nerve attached—submerged in an organ bath.
• Evaluation: The phrenic nerve is electrically stimulated, and the force of the resulting diaphragm muscle contractions is measured.
  • If the patient's serum contains neutralizing antibodies, the antibodies bind to the toxin in the organ bath, preventing it from blocking acetylcholine release. The diaphragm muscle continues to contract normally.
  • If no neutralizing antibodies are present, the toxin paralyses the nerve-muscle junction, and the contractions cease.
  • The MHDA is extremely sensitive, capable of detecting neutralizing antibodies at concentrations as low as 1.82 mIU/mL. It provides definitive proof of immunogenic resistance.

---

What Can I Do If Botox Stops Working — Switch to Xeomin/Daxxify, Switch to Myobloc, or Take a Break?

If a diagnostic workup confirms that your secondary treatment failure is indeed driven by neutralizing antibodies, continuing with standard Botox injections is clinically counterproductive. It will fail to produce results and will only continue to stimulate memory B-cells, maintaining high antibody titers.

However, patients have three evidence-based pathways to explore:

Pathway 1: Switch to a Complexing-Protein-Free Type A Toxin (Xeomin or Daxxify)

The most common and successful strategy is to switch to a pure, complexing-protein-free formulation. Because incobotulinumtoxinA (Xeomin) and daxibotulinumtoxinA (Daxxify) lack the adjuvant accessory proteins, they present a significantly lower antigenic profile to the immune system.

• The Scientific Evidence: In a clinical study summarized in the Dove Press review of treatment failure (Wanitphakdeedecha et al.), approximately 30% of patients who had developed secondary resistance to complexed toxins (Botox or Dysport) successfully regained their clinical response when switched to the complexing-protein-free Xeomin.
• Neutralizing Antibody Decline: More recently, a landmark study published in MDPI Toxins (Martin et al., 2024) documented the case of an aesthetic patient who had developed high titers of neutralizing antibodies (confirmed via mouse bioassay). Instead of stopping treatment, the patient was transitioned to incobotulinumtoxinA (Xeomin) for their masseter and facial injections. Under continuous, exclusive treatment with the complexing-protein-free toxin, the patient's neutralizing antibody titers progressively declined below the detection limit of 1.82 mIU/mL, and their clinical responsiveness fully returned. This demonstrated that without the accessory-protein adjuvants, the immune system eventually stops actively producing antibodies, allowing the existing titers to wash out.

Pathway 2: Switch to a Different Serotype (Botulinum Toxin Type B / Myobloc)

All major aesthetic neuromodulators (Botox, Dysport, Xeomin, Jeuveau, Daxxify) are derived from botulinum toxin Type A (for the serotype background, see our botulinum toxin Type A vs Type B comparison). They all target and cleave the same intracellular protein, SNAP-25.

If a patient has developed neutralizing antibodies against Type A, those antibodies are highly specific to the Type A protein structure. They will not cross-react with botulinum toxin Type B.

• RimabotulinumtoxinB (Myobloc): Myobloc is the only FDA-approved Type B toxin on the market. Instead of cleaving SNAP-25, Type B cleaves synaptobrevin (also known as vesicle-associated membrane protein or VAMP), a completely different protein involved in neurotransmitter release.
• The Tradeoffs: While switching to Myobloc will bypass Type A antibodies and successfully relax the muscles, it has significant clinical drawbacks for cosmetic use:
  1. High Immunogenicity: Type B is far more immunogenic than current type A formulations. Because a much higher protein load is required for equivalent biological activity, neutralizing antibody formation is common — de novo NAb rates in the pivotal type B trials ranged from 33% to 44% over 18 months, and a meta-analysis of 1,257 type B–treated patients put overall NAb prevalence near 42% (versus roughly 0.5–2.5% for type A). You can simply trade one antibody problem for another.
  2. Shorter Duration: Myobloc's effect for cosmetic facial use tends to wear off sooner than type A — frequently before the 3-to-4-month duration typical of type A toxins. (Its FDA label cites 12–16 weeks for the approved cervical-dystonia indication at high therapeutic doses; cosmetic doses behave differently.)
  3. Acidic pH and Discomfort: Myobloc is formulated in an acidic solution (pH ~5.6), which causes a temporary but intense burning sensation upon injection. It also has a wider diffusion profile, making precise targeting in small facial muscles highly challenging. Therefore, Myobloc is generally considered a short-term or secondary option rather than a permanent cosmetic solution.

Pathway 3: The Treatment Holiday (Multi-Year Break)

If a patient has high neutralizing antibody titers and does not respond to a CPF toxin, the only remaining option is to undergo a complete "treatment holiday"—a prolonged period with absolutely no exposure to any botulinum toxin product.

• Duration of the Holiday: Neutralizing antibodies are produced by long-lived plasma cells in the bone marrow. These cells can survive and continue secreting antibodies for years. A review of long-term dystonia patients by Dressler et al. showed that NAb titers decline very slowly. The mean time required for antibody titers to fall to clinically insignificant levels was 3,881 ± 2,468 days—equivalent to roughly 3 to 10 years.
• Restart Protocol: Attempting to restart injections after a six-month or one-year break is highly likely to trigger an immediate, anamnestically boosted antibody response. Patients must wait until EDB or MHDA testing confirms that their antibody titers have completely cleared before attempting to resume treatments. Crucially, when resuming, the injector must exclusively use a complexing-protein-free toxin (Xeomin or Daxxify) to prevent re-immunization.

---

How Do I Prevent It — Spacing, Booster Doses, and the 3-Month Rule?

Because resolving antibody-mediated treatment failure is incredibly difficult, prevention is the absolute gold standard of clinical practice. Every injector and patient should follow the immunogenicity-minimization rules encoded directly within the FDA prescribing guidelines:

1. Respect the 3-Month Spacing Rule (Minimum 12 Weeks): The single most critical driver of antibody formation is the frequency of exposure. The FDA prescribing label for Botox Cosmetic explicitly states that the cumulative dose should not exceed 400 units within a 3-month interval, and that the minimum time between treatments should be at least 12 weeks. Injecting a patient every 6 to 8 weeks because "a few movement lines came back" keeps the immune system constantly exposed to the antigen, increasing the risk of memory B-cell activation.
2. Strictly Avoid "Booster" or "Touch-Up" Doses: It is common practice for patients to return to their injector two weeks after a treatment to request a "touch-up" or "booster" for a persistent movement line. From an immunological perspective, a booster dose is a vaccination booster. The initial injection primes the immune system, and the secondary injection two weeks later provides a highly potent secondary antigenic stimulation, dramatically increasing antibody production. Injectors should perform thorough initial assessments, inject the full required dose in a single session, and wait at least 12 weeks before injecting that area again—even if minor muscle asymmetry remains.
3. Minimize the Cumulative Antigen Load: Use the lowest effective dose to achieve the desired clinical result. The "baby Botox" philosophy of using smaller, targeted unit counts is immunologically sound, provided it is not paired with frequent injections.
4. Initiate Treatment with Complexing-Protein-Free Toxins: For young patients who are beginning a multi-decade journey of neuromodulator treatments, starting with a complexing-protein-free toxin like Xeomin or Daxxify is a highly logical preventive strategy. By eliminating the adjuvant complexing proteins from the very first injection, the cumulative lifetime risk of developing neutralizing antibodies is minimized.

---

Frequently Asked Questions

If my Botox stopped working after years, is it permanent, and how long do I have to wait before it might work again?

If the failure is caused by neutralizing antibodies, the loss of response is not permanent, but it is long-lasting. You must undergo a complete "treatment holiday" during which you receive no botulinum toxin of any serotype. Clinical studies show that antibody titers take an average of 3 to 10 years to clear. Attempting to inject sooner will simply reactivate the antibody response.

Should I ask my injector for a free 'top-up' at two weeks, or does that raise my antibody risk?

You should strictly avoid two-week "top-up" or booster doses. Injecting a small amount of toxin two weeks after your primary treatment acts as a booster vaccine, triggering a strong secondary immune response that significantly increases your risk of developing neutralizing antibodies. If you have asymmetric movement, wait until your next scheduled 12-week session to adjust the dose.

If I switch from Botox to Xeomin or Daxxify, do the units convert one-to-one?

• Botox to Xeomin: The conversion is 1:1. Clinical trials and consensus guidelines have confirmed that 20 units of Botox Cosmetic are equivalent in clinical potency and diffusion to 20 units of Xeomin.
• Botox to Daxxify: The conversion is not 1:1. Daxxify is formulated differently; its standard glabellar dose is 40 units, which is equivalent to 20 units of Botox. This is roughly a 2:1 ratio (2 units of Daxxify for every 1 unit of Botox).
• Note: The FDA labels explicitly state that units of botulinum toxin are not interchangeable across brands. Your provider must calibrate your dose using the specific brand's protocol.

Can I just switch to Myobloc (Type B) permanently if Type A stops working?

No. While Myobloc (Type B) will successfully bypass Type A antibodies, it is not a viable permanent cosmetic solution. De novo neutralizing antibody formation in the type B trials ranged from 33% to 44% within roughly 18 months due to the high protein load required. Additionally, Myobloc's cosmetic effect tends to be shorter-lived than type A, it causes a painful burning sensation upon injection due to its acidic pH (~5.6), and it has a wide diffusion profile that increases the risk of drooping adjacent muscles.

---

Sources

• FDA Drugs@FDA, OnabotulinumtoxinA (Botox) approval history: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103000
• FDA prescribing information, DaxibotulinumtoxinA-lanm (Daxxify), BLA 761127: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761127s000lbl.pdf
• FDA prescribing information, IncobotulinumtoxinA (Xeomin), BLA 125387: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125387lbl.pdf
• Albrecht et al., High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy (Neurology 2019): https://pubmed.ncbi.nlm.nih.gov/30464031/
• Causes of Botulinum Toxin Treatment Failure (Dove Press / PMC9188316, 2022): https://pmc.ncbi.nlm.nih.gov/articles/PMC9188316/
• Continuous Treatment with IncobotulinumtoxinA Despite BoNT/A Neutralizing Antibodies (MDPI Toxins, 2024): https://pmc.ncbi.nlm.nih.gov/articles/PMC11510976/
• Complexing proteins in botulinum toxin type A drugs (PMC3010823): https://pmc.ncbi.nlm.nih.gov/articles/PMC3010823/
• Exploring Nonresponse to Botulinum Toxin in Aesthetics (Kroumpouzos, JMIR Dermatology 2025): https://derma.jmir.org/2025/1/e69960
• EDB test original methods paper (PubMed 12451609): https://pubmed.ncbi.nlm.nih.gov/12451609/
• British Neurotoxin Network — Non-Responders in Cervical Dystonia guideline: https://www.neurotoxinnetwork.org/british-neurotoxin-network-therapeutic-guidelines-non-responders-cervical-dystonia/